Digital technologies for cognitive assessment to accelerate drug development in Alzheimer's disease

For many neurological and psychiatric diseases, novel therapeutics have been elusive for decades. By focusing on attention interference in Alzheimer's disease (AD), we provide a future vision on how emerging mobile, computer, and device‐based cognitive tools are converting classically noisy, su...

Full description

Saved in:
Bibliographic Details
Published inClinical pharmacology and therapeutics Vol. 98; no. 5; pp. 475 - 476
Main Authors Leurent, C, Ehlers, MD
Format Journal Article
LanguageEnglish
Published United States 01.11.2015
Subjects
Alzheimer Disease - diagnosis
Alzheimer Disease - drug therapy
Alzheimer Disease - psychology
Cognition Disorders - diagnosis
Cognition Disorders - drug therapy
Cognition Disorders - psychology
Drug Discovery - methods
Drug Discovery - trends
Humans
Smartphone - trends
Smartphone - utilization
Telemedicine - trends
Telemedicine - utilization
Online AccessGet full text

Cover

More Information
Summary:For many neurological and psychiatric diseases, novel therapeutics have been elusive for decades. By focusing on attention interference in Alzheimer's disease (AD), we provide a future vision on how emerging mobile, computer, and device‐based cognitive tools are converting classically noisy, subjective, data‐poor clinical endpoints associated with neuropsychiatric disease assessment into a richer, scalable, and objective set of measurements. Incorporation of such endpoints into clinical drug trials holds promise for more quickly and efficiently developing new medicines.
ISSN:0009-9236
1532-6535
DOI:10.1002/cpt.212